Engineering antibodies for cancer therapy

Current Science

Volumn 96, Issue 12, 2009, Pages 1592-1600

  Choudhary, Rakesh K ^a   Batra, Janendra K ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Antibodies; Cancer; Genetic engineering; Immunotherapy

Indexed keywords

EID: 70349221576     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Kohler, G. and Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256, 495-497.
2. Van Boxel, J. A., Stobo, J. D., Paul, W. E. and Green, I., Antibody- dependent lymphoid cell-mediated cytotoxicity: no requirement for thymus-derived lymphocytes. Science, 1972, 175, 194- 196.
3. May, J. E., Green, I. and Frank, M. M., The alternate complement pathway in cell damage: antibody-mediated cytolysis of erythrocytes and nucleated cells. J. Immunol., 1972, 109, 595- 601.
4. Cohn, Z. A., The structure and function of monocytes and macrophages. Adv. Immunol., 1968, 9, 163-214.
5. Kindt, T. J. et al., Immunology, W.H. Freeman, New York, 2007, 6th edn, p. 96.
6. Presta, L. G., Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev., 2006, 58, 640-656.
7. Natsume, A. et al., Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res., 2008, 68, 3863-3872.
8. Kanda, Y. et al., Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology, 2007, 17, 104-118.
9. Zhou, Q. et al., Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol. Bioeng., 2008, 99, 652-665.
10. Lazar, G. A. et al., Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA, 2006, 103, 4005-4010.
11. McEarchern, J. A. et al., Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumour activities. Blood, 2007, 109, 1185-1192.
12. Zhukovsky, E. et al., XmAb Fc engineered anti-CD19 monoclonal antibodies with enhanced in vitro efficacy against multiple lymphoma cell lines. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol., 2007, 25, 3021.
13. Bernstein, I. D., Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia, 2000, 14, 474-475.
14. Sievers, E. L. et al., Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol., 2001, 19, 3244-3254.
15. Boghaert, E. R. et al., The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin. Int. J. Oncol., 2008, 32, 221-234.
16. Oflazoglu, E., Kissler, K. M., Sievers, E. L., Grewal, I. S. and Gerber, H. P., Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br. J. Haematol., 2008, 142, 69-73.
17. Galsky, M. D. et al., Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol., 2008, 26, 2147-2154.
18. Patra, C. R. et al., Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res., 2008, 68, 1970-1978.
19. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I. and King, C. R., Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 1992, 89, 5867- 5871.
20. Batra, J. K. et al., Antitumour activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 1989, 86, 8545-8549.
21. Goyal, A. and Batra, J. K., Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. Biochem. J., 2000, 345, 247-254.
22. Qiu, X. C. et al., Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumour growth. Mol. Cancer Ther., 2008, 7, 1890-1899.
23. Kioi, M., Seetharam, S. and Puri, R. K., Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol. Cancer Ther., 2008, 7, 1579-1587.
24. Multani, P. S., O'Day, S., Nadler, L. M. and Grossbard, M. L., Phase II clinical trial of bolus infusion anti-B4 blocked Ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res., 1998, 4, 2599-2604.
25. Frankel, A. E., Powell, B. L., Hall, P. D., Case, L. D. and Kreitman, R. J., Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin. Cancer Res., 2002, 8, 1004-1013.
26. LeMaistre, C. F. et al., Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood, 1998, 91, 399-405.
27. Messmann, R. A. et al., A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated Ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19 (+), CD22 (+) B cell lymphoma. Clin. Cancer Res., 2000, 6, 1302-1313.
28. Zalcberg, J. R. et al., A phase I/II study of the intralesional injection of Ricin-monoclonal antibody conjugates in patients with hepatic metastases. Eur. J. Cancer, 1994, 30A, 1227-1231.
29. Winer, L. M. et al., Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant Ricin A chain immunoconjugate. Cancer Res., 1989, 49, 4062-4067.
30. Rathore, D. and Batra, J. K., Cytotoxic activity of ribonucleolytic toxin restriction-based chimeric toxin targeted to epidermal growth factor receptor. FEBS Lett., 1997, 407, 275-279.
31. Kreitman, R. J. and Pastan, I., Immunotoxins in the treatment of hematologic malignancies. Curr. Drug Targets, 2006, 7, 1301-1311.
32. Pastan, I., Hassan, R., FitzGerald, D. J. and Kreitman, R. J., Immunotoxin treatment of cancer. Annu. Rev. Med., 2007, 58, 221-237.
33. Pastan, I., Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol. Immunother., 2003, 52, 338-341.
34. Pastan, I., Immunotoxins in cancer therapy. Curr. Opin. Invest. Drugs, 2002, 3, 1089-1091.
35. Benhar, I., Wang, Q. C., FitzGerald, D. and Pastan, I., Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J. Biol. Chem., 1994, 269, 13398-13404.
36. Wang, Q. C., Pai, L. H., Debinski, W., FitzGerald, D. J. and Pastan, I., Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. Cancer Res., 1993, 53, 4588-4594.
37. Tsutsumi, Y., Onda, M., Nagata, S., Lee, B., Kreitman, R. J. and Pastan, I., Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) improves antitumour activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA, 2000, 97, 8548-8553.
38. Filpula, D. et al., Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug. Chem., 2007, 18, 773-784.
39. Reardan, D. T. et al., Antibodies against metal chelates. Nature, 1985, 316, 265-268.
40. Chang, C. H. et al., Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol. Cancer Ther., 2002, 1, 553-563.
41. Goldenberg, D. M. and Sharkey, R. M., Novel radiolabeled antibody conjugates. Oncogene, 2007, 26, 3734-3744.
42. Wu, A. M. and Senter, P. D., Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnol., 2005, 23, 1137-1146.
43. Sharkey, R. M. and Goldenberg, D. M., Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin., 2006, 56, 226-243.
44. Bagshawe, K. D. et al., A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer, 1988, 58, 700-703.
45. Coelho, V. et al., Design, construction, and in vitro analysis of A33scFv:: CDy, a recombinant fusion protein for antibodydirected enzyme prodrug therapy in colon cancer. Int. J. Oncol., 2007, 31, 951-957.
46. Bhatia, J. et al., Catalytic activity of an in vivo tumour targeted anti-CEA scFv:: carboxypeptidase G2 fusion protein. Int. J. Cancer, 2000, 85, 571-577.
47. Bagshawe, K. D., Sharma, S. K. and Begent, R. H., Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin. Biol. Ther., 2004, 4, 1777-1789.
48. Bagshawe, K. D., Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Rev. Anticancer Ther., 2006, 6, 1421-1431.
49. Simister, N. E. and Mostov, K. E., An Fc receptor structurally related to MHC class I antigens. Nature, 1989, 337, 184-187.
50. Story, C. M., Mikulska, J. E. and Simister, N. E., A major histo-compatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med., 1994, 180, 2377-2381.
51. Ghetie, V. et al., Increasing the serum persistence of an IgG fragment by random mutagenesis. Nature Biotechnol., 1997, 15, 637-640.
52. Hornick, J. L. et al., Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumours. J. Nucl. Med., 2000, 41, 355-362.
53. Hinton, P. R. et al., Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem., 2004, 279, 6213-6216.
54. Vaccaro, C., Zhou, J., Ober, R. J. and Ward, E. S., Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nature Biotechnol., 2005, 23, 1283-1288.
55. Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K. and Morgan Jr, A. C., Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res., 1985, 45, 879-885.
56. Shawler, D. L., Bartholomew, R. M., Smith, L. M. and Dillman, R. O., Human immune response to multiple injections of murine monoclonal IgG. J. Immunol., 1985, 135, 1530-1535.
57. Morrison, S. L., Johnson, M. J., Herzenberg, L. A. and Oi, V. T., Chimeric human-antibody molecules - mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA, 1984, 81, 6851-6855.
58. Boulianne, G. L., Hozumi, N. and Shulman, M. J., Production of functional chimaeric mouse-human antibody. Nature, 312, 1984, 643-646.
59. Khazaeli, M. B., Conry, R. M. and LoBuglio, A. F., Human immune response to monoclonal antibodies. J. Immunother. Emphasis Tumor Immunol., 1994, 15, 42-52.
60. Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S. and Winter, G., Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 1986, 321, 522-525.
61. Verhoeyen, M., Milstein, C. and Winter, G., Reshaping human antibodies: grafting an antilysozyme activity. Science, 1988, 239, 1534-1536.
62. Powelson, J. A. et al., CDR-grafted OKT4A monoclonal antibody in cynomolgus renal allograft recipients. Transplantation, 1994, 57, 788-793.
63. Ellis, J. H. et al., Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol., 1995, 155, 925-937.
64. Iwahashi, M., Milenic, D. E., Padlan, E. A., Bei, R., Schlom, J. and Kashmiri, S. V., CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol. Immunol., 1999, 36, 1079-1091.
65. Caldas, C., Coelho, V., Kalil, J., Moro, A. M., Maranhão, A. Q. and Brígido, M. M., Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen. Mol. Immunol., 2003, 39, 941-952.
66. Hou, S. et al., Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modeling. J. Biochem., 2008, 144, 115-120.
67. Scott, A. M. et al., A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 2003, 9, 1639-1647.
68. Welt, S. et al., Phase I study of anticolon cancer humanized antibody A33. Clin. Cancer Res., 2003, 9, 1338-1346.
69. Almagro, J. C., Identification of differences in the specificity determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires. J. Mol. Recognit., 2004, 17, 132-143.
70. Gonzales, N. R., Padlan, E. A., De Pascalis, R., Schuck, P., Schlom, J. and Kashmiri, S. V., Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. Mol. Immunol., 2003, 40, 337-349.
71. Gonzales, N. R., Padlan, E. A., De Pascalis, R., Schuck, P., Schlom, J. and Kashmiri, S. V., SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. Mol. Immunol., 2004, 41, 863-872.
72. Kashmiri, S. V., De Pascalis, R., Gonzales, N. R. and Schlom, J., SDR grafting - a new approach to antibody humanization. Methods, 2005, 36, 25-34.
73. Baker, M. P. and Jones, T. J., Identification and removal of immunogenicity in therapeutic proteins. Curr. Opin. Drug Discov. Dev., 2007, 10, 219-227.
74. Reche, P. A., Glutting, J. P., Zhang, H. and Reinherz, E. L., Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics, 2004, 56, 405-419.
75. Hertz, T. and Yanover, C., PepDist: A new framework for protein-peptide binding prediction based on learning peptide distance functions. BMC Bioinf. (Suppl 1), 2006, 7, S3-S17.
76. Bander, N. H., Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S. and Goldsmith, S. J., Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol., 2005, 23, 4591-4601.
77. Padlan, E. A., A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol., 1991, 28, 489-498.
78. Roguska, M. A. et al., Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA, 1994, 91, 969-973.
79. Barlow, D. J., Edwards, M. S. and Thornton, J. M., Continuous and discontinuous protein antigenic determinants. Nature, 1986, 322, 747-748.
80. Benjamin, D. C., et al., The antigenic structure of proteins: a reappraisal. Annu. Rev. Immunol., 1984, 2, 67-101.
81. Novotny, J. et al., Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). Proc. Natl. Acad. Sci. USA, 1986, 83, 226-230.
82. Staelens, S. et al., Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol. Immunol., 2006, 43, 1243-1257.
83. Frankel, A. E., Reducing the immune response to immunotoxin. Clin. Cancer Res., 2004, 10, 13-15.
84. Gao, J. et al., PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumour progression with reduced toxicity and immunogenicity. Breast Cancer Res. Treat., 2009, 115, 29-41.
85. Onda, M. et al., Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J. Immunol., 2006, 17, 8822-8834.
86. Onda, M., Beers, R., Xiang, L., Nagata, S., Wang, Q. C. and Pastan, I., An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc. Natl. Acad. Sci. USA, 2008, 105, 11311-11316.
87. Marasco, W. A. and Sui, J., The growth and potential of human antiviral monoclonal antibody therapeutics. Nature Biotechnol., 2007, 25, 1421-1434.
88. Carter, P. J., Potent antibody therapeutics by design. Nature Rev. Immunol., 2006, 6, 343-357.
89. Hoogenboom, H. R., Selecting and screening recombinant antibody libraries. Nature Biotechnol., 2005, 23, 1105-1116.
90. Ho, M., Nagata, S. and Pastan, I., Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc. Natl. Acad. Sci. USA, 2006, 103, 9637-9642.
91. Griffiths, A. D. et al., Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J., 1994, 13, 3245-3260.
92. Hawkins, R. E., Russell, S. J. and Winter, G., Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol., 1992, 226, 889-896.
93. Hudson, P. J. and Souriau, C., Engineered antibodies. Nature Med., 2003, 9, 129-134.
94. Jain, M., Kamal, N. and Batra, S. K., Engineering antibodies for clinical applications. Trends Biotechnol., 2007, 25, 307-316.
95. Sloan, S. E. et al., Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine, 2007, 25, 2800-2810.
96. Coughlin, M. et al., Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology, 2007, 361, 93-102.
97. Greenough, T. C. et al., Development and characterization of a severe acute respiratory syndrome-associated coronavirusneutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J. Infect. Dis., 2005, 191, 507-514.
98. Bernasconi, N. L., Traggiai, E. and Lanzavecchia, A., Maintenance of serological memory by polyclonal activation of human memory B cells. Science, 2002, 298, 2199-2202.
99. Traggiai, E. et al., An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nature Med., 2004, 10, 871-875.
100. Simmons, C. P. et al., Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med., 2007, 4, e178.
101. Pantoliano, M. W. et al., Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli. Biochemistry, 1991, 30, 10117-10125.
102. Huston, J. S. et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA, 1988, 85, 5879-5883.
103. Holliger, P., Prospero, T. and Winter, G., 'Diabodies': small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA, 1993, 90, 6444-6448.
104. Iliades, P., Kortt, A. A. and Hudson, P. J., Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett., 1997, 409, 437-441.
105. Yu, K. et al., Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk. Lymphoma, 2008, 49, 1368-1373.
106. Bühler, P. et al., A bispecific diabody directed against prostatespecific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol. Immunother., 2008, 57, 43-52.
107. Schmiedl, A., Zimmermann, J., Scherberich, J. E., Fischer, P. and Dübel, S., Recombinant variants of antibody 138H11 against human gamma-glutamyltransferase for targeting renal cell carcinoma. Hum. Antibodies, 2006, 15, 81-94.
108. Adams, G. P. and Weiner, L. M., Monoclonal antibody therapy of cancer. Nature Biotechnol., 2005, 23, 1147-1157.
109. Robert, N. et al., Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol., 2006, 24, 2786-2792.
110. Maartje, L., Roodhart, J. M. and Voest, E. E., Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist, 2007, 12, 443-450.
111. Senior, K., Early phase III results for rituximab. Lancet Oncol., 2005, 6, 925.
112. Sorbero, A. F. et al., EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol., 2008, 26, 2311-2319.
113. Feldman, E. J. et al., Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol., 2005, 23, 4110-4116.
114. Hassan, R. et al., Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res., 2007, 13, 5144-5149.
115. Kreitman, R. J. et al., Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol., 2005, 23, 6719-6729.
116. Olsen, E. et al., Pivotal phase III trial of two dose levels of Denileukin diftitox for the treatment of cutaneous t-cell lymphoma. J. Clin. Oncol., 2001, 19, 376-388.
117. Schnell, R. et al., Clinical evaluation of Ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann. Oncol., 2003, 14, 729-736.
118. Gibson, T. B., Ranganathan, A. and Grothey, A., Randomized phase III trial results of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer, 2006, 6, 29-31.
119. Hartung, G. et al., Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomised phase III study. Onkologie, 2005, 28, 347-350.
120. Christiansen, J. and Rajasekaran, A. K., Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther., 2004, 3, 1493-1501.
121. Thurber, G. M., Schmidt, M. M. and Wittrup, K. D., Antibody tumour penetration: Transport opposed by systemic and antigenmediated clearance. Adv. Drug Deliv. Rev., 2008, 60, 1421-1434.